A study reports the development of a new mouse model for atopic dermatitis, an inflammatory skin disorder commonly known as eczema. The findings, published in Cell Reports, suggest that mast cells, a type of immune cell, are critical for both spontaneous and allergen-induced eczema. The study, led by researchers at the La Jolla Institute for Allergy and Immunology, was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health.
Eczema is estimated to affect approximately one in five infants and one in fifty adults in the United States. The causes underlying the disorder are unclear. Previous research has suggested a role for imbalanced immune responses and impaired skin defenses, as well as overproduction of thymic stromal lymphopoietin (TSLP), a protein that promotes inflammation. While different mouse models for eczema have been developed, research examining how they are linked to human disease is still ongoing.
In the current study, researchers show that mice lacking phospholipase C-ß3 (PLC- ß3), an enzyme that helps regulate inflammation, develop a skin disorder similar to human eczema, with high levels of TSLP. In this model, disease progression depends on the accumulation of mast cells and the activity of a signaling protein called Stat5. This role for mast cells and Stat5 in eczema was not previously known. The researchers also examined skin lesions of eczema patients and found that some had accumulation of mast cells expressing active Stat5. They identified changes, or polymorphisms, in genes that regulate PLC- ß3 and Stat5 that are more common in patients with eczema. With these links to human disease, the targets identified in the mouse model may offer potential new strategies for treating this common disorder in people.
ARTICLE: T. Ando et al. Critical role for mast-cell Stat5 activity in skin inflammation. Cell Reports. DOI: 10.1016/j.celrep.2013.12.029 (2014).
Marshall Plaut, M.D., chief of the Food Allergy, Atopic Dermatitis and Allergic Mechanisms Section in NIAID's Division of Allergy, Immunology and Transplantation, is available to discuss the findings.
To schedule interviews, please contact Linda Huynh, (301) 402-1663, linda.huynh@nih.gov.
VIDEO: http://www.youtube.com/watch?v=p-NVeGnK71w
Eczema is a common skin disorder in the United States, and NIH-funded studies continue to explore treatment options for patients.
Credit: NIAID
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery Into Health®
Journal
Cell Reports